

# Exhibit I

Table A-II-1  
PHARMACOKINETIC DATA (Continued)

AVAILABILITY (ORAL) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml min <sup>-1</sup> kg <sup>-1</sup> )	NO. DPT (hr/pt/kg)	HALF-LIFE (hours)	EFFECTIVE CONCENTRATIONS	TOXIC CONCENTRATIONS
53 ± 20 <sup>a</sup> ↓ Aged, Chr	Negligible	95 <sup>b</sup>	7.5 ± 2.7 <sup>a</sup> ↓ Aged, Chr ↑ Urem	0.34 ± 0.09 <sup>a</sup> ↓ Aged, Chr	0.7 ± 0.3 <sup>a</sup> ↓ Aged, Chr ↑ Urem	—	—
<p>Increases upon multiple dosing to 70 ± 26%.</p> <p><sup>a</sup>Solubility for CYP2C19 and CYP3A. Patients deficient in CYP2C19 exhibit a clearance of 1.0 ± 0.2 ml min<sup>-1</sup> kg<sup>-1</sup> and a half-life of 2.7 ± 0.7 hours.</p> <p><sup>b</sup>Decreases upon multiple dosing.</p> <p><sup>c</sup>See text.</p>							
62 ± 15 <sup>a</sup> ↓ Aged, Chr, Fem	5	73 ± 2 <sup>b</sup>	5.9 ± 2.6 ↓ Aged, Chr, Fem ↑ Child	1.9 ± 0.5 ↓ Aged, Chr	3.5 ± 1.2 <sup>a</sup> ↓ Aged, Chr ↑ Child	—	—
<p><sup>a</sup>In 25 acute patients, 62 ± 10 years, F = 86 ± 26%.</p> <p><sup>b</sup>Blood-to-plasma concentration ratio = 0.85.</p>							
33	46 ± 4	92.2 ± 0.6	6.1 ± 1.7	0.33 ± 0.09 <sup>a</sup>	0.4-0.7 ↑ Urem	See Chapter 45	—
<p><sup>a</sup>See text.</p>							
95-100	Negligible	>99.5 <sup>a</sup> ↓ Urem ↑ Aged, Chr, Fem	0.035-0.04 <sup>a</sup> ↓ Aged, Chr, Fem	0.14-0.28 <sup>a</sup> ↓ Aged, Chr, Fem	21-29 <sup>a</sup> ↓ Aged, Chr, Fem	—	—
<p><sup>a</sup>Decreases with increasing concentrations.</p> <p><sup>b</sup>Mean total clearance and volume of distribution for 300- to 1200-mg doses. Unbound clearance is constant (about 40 ml min<sup>-1</sup> kg<sup>-1</sup>) over this dose range.</p> <p><sup>c</sup>Accumulation half-life, longer. 60-hour terminal half-life is not consistent with time to achieve steady-state.</p>							

97 ± 11	<1	98 ± 1.8 ↑ Urem, Alb AVH, Cirr	1.05 ± 0.36 ↑ HTL, Snsk, Urem, ↓ HTL, Aged, AVH, Cirr	0.60 ± 0.20 ↑ Urem, ↓ Aged, AVH, Cirr	8.0 ± 2.4 ↑ Urem, Neo HTL, Aged, ↓ Aged, AVH, Cirr, LTH, Preg	—
---------	----	--------------------------------------	--	--	---	---

\*CL/F of unbound drug is unchanged in uremia.

Reference: Sauts J, Loh S, Dittling M, Vollmar-Loren A, Olsen K.L, Verne M, Andrasen F and Andrasen FB. Bioavailability and pharmacokinetics of oxacupam. *Eur J Clin Pharmacol*, 1985, 33:385-389.

Low	5 ± 2	95-98*	5.5 ± 3.4 <sup>a</sup> ↓ Child	2.0 ± 1.2 <sup>b</sup> ↓ Child	3 ± 1 <sup>d</sup>	—
-----	-------	--------	-----------------------------------	-----------------------------------	--------------------	---

\*A recent report suggests binding to dialysis filtrate devices leads to overestimates of 88% protein-bound.

<sup>a</sup>Stable distribution, which would also appear as saturable clearance, has been suggested.

<sup>b</sup>CYP2C8 and CYP2A4 substrate.

<sup>c</sup>Average accumulation half-life. Longer terminal half-lives, up to 30 hours have been reported.

Reference: Soumichou D.S. and Reiling M.V. Clinical pharmacokinetics of pectinol. *Clin Pharmacol*, 1994, 27:256-269.

—	67 ± 18 ↔ CFB	7 ± 2 ↔ Neo, Fem, Preg, Urem	1.8 ± 0.4 ↓ Aged, Urem ↔ Cirr, CFB	0.26 ± 0.07 ↔ CFB, ↑ Cirr	2.3 ± 0.4 ↑ Aged, Urem, Cirr ↔ CFB	0.25 ± 0.07 $\mu$ g/ml <sup>a</sup> 0.40 $\mu$ g/ml <sup>b</sup>
---	------------------	------------------------------------	--	---------------------------------	---	---

\*50% decrease in twitch tension;  
95% decrease in twitch tension.

Reference: Shanks C.A. Pharmacokinetics of the nondepolarizing neuromuscular relaxants applied to calculation of bolus and infusion dosage regimens. *Anesthesiology*, 1986, 64:72-86.

Dose-dependent	<2	95	8.6 ± 3.2 <sup>a,b</sup> ↓ Cirr, Aged	17 ± 10 <sup>c</sup>	17 ± 3 <sup>d</sup> ↑ Cirr, Aged	—
----------------	----	----	--	----------------------	-------------------------------------	---

\*CL/F for multiple dosing data in extensive metabolizers. Single-dose data significantly higher. In poor metabolizers CL/F = 5.0 ± 2.1 ml · min<sup>-1</sup> · kg<sup>-1</sup> for multiple dosing.

<sup>a</sup>CYP2D6 substrate which exhibits saturable metabolism.

<sup>b</sup>For multiple dosing in extensive metabolizers. In poor metabolizers t<sub>1/2</sub> = 41 ± 8 hours.

Reference: Stodrup S.H., Bensen K., Gram L.F., Hella J., Sjöbo E., Allen A., Allen G.D., Cooper S.M., Mellows G., Teister T.C.G. and Ziesman B.D. The relationship between paroxetine and the sparteine oxidation polymorphism. *Clin Pharmacol Ther*, 1992, 51:78-87.

Key: Abil = edile; Aged = aged; Alb = hypoalbuminemia; Arth = arthritis; At Fib = atrial fibrillation; AUC = area under the curve; AVH = acute viral hepatitis; Bmn = bmn patients; CAD = coronary artery disease; Colase = celase disease; CFB = cyclic fibrosis; CHF = congestive heart failure; Child = children; Cirr = cirrhosis; CYP2D6 = cytochrome P450 2D6; CYP2C8 = cytochrome P450 2C8; CYP2A4 = cytochrome P450 2A4; CYP2C19 = cytochrome P450 2C19; CYP2C9 = cytochrome P450 2C9; CYP2C10 = cytochrome P450 2C10; CYP2C11 = cytochrome P450 2C11; CYP2C12 = cytochrome P450 2C12; CYP2C13 = cytochrome P450 2C13; CYP2C14 = cytochrome P450 2C14; CYP2C15 = cytochrome P450 2C15; CYP2C16 = cytochrome P450 2C16; CYP2C17 = cytochrome P450 2C17; CYP2C18 = cytochrome P450 2C18; CYP2C19 = cytochrome P450 2C19; CYP2C20 = cytochrome P450 2C20; CYP2C21 = cytochrome P450 2C21; CYP2C22 = cytochrome P450 2C22; CYP2C23 = cytochrome P450 2C23; CYP2C24 = cytochrome P450 2C24; CYP2C25 = cytochrome P450 2C25; CYP2C26 = cytochrome P450 2C26; CYP2C27 = cytochrome P450 2C27; CYP2C28 = cytochrome P450 2C28; CYP2C29 = cytochrome P450 2C29; CYP2C30 = cytochrome P450 2C30; CYP2C31 = cytochrome P450 2C31; CYP2C32 = cytochrome P450 2C32; CYP2C33 = cytochrome P450 2C33; CYP2C34 = cytochrome P450 2C34; CYP2C35 = cytochrome P450 2C35; CYP2C36 = cytochrome P450 2C36; CYP2C37 = cytochrome P450 2C37; CYP2C38 = cytochrome P450 2C38; CYP2C39 = cytochrome P450 2C39; CYP2C40 = cytochrome P450 2C40; CYP2C41 = cytochrome P450 2C41; CYP2C42 = cytochrome P450 2C42; CYP2C43 = cytochrome P450 2C43; CYP2C44 = cytochrome P450 2C44; CYP2C45 = cytochrome P450 2C45; CYP2C46 = cytochrome P450 2C46; CYP2C47 = cytochrome P450 2C47; CYP2C48 = cytochrome P450 2C48; CYP2C49 = cytochrome P450 2C49; CYP2C50 = cytochrome P450 2C50; CYP2C51 = cytochrome P450 2C51; CYP2C52 = cytochrome P450 2C52; CYP2C53 = cytochrome P450 2C53; CYP2C54 = cytochrome P450 2C54; CYP2C55 = cytochrome P450 2C55; CYP2C56 = cytochrome P450 2C56; CYP2C57 = cytochrome P450 2C57; CYP2C58 = cytochrome P450 2C58; CYP2C59 = cytochrome P450 2C59; CYP2C60 = cytochrome P450 2C60; CYP2C61 = cytochrome P450 2C61; CYP2C62 = cytochrome P450 2C62; CYP2C63 = cytochrome P450 2C63; CYP2C64 = cytochrome P450 2C64; CYP2C65 = cytochrome P450 2C65; CYP2C66 = cytochrome P450 2C66; CYP2C67 = cytochrome P450 2C67; CYP2C68 = cytochrome P450 2C68; CYP2C69 = cytochrome P450 2C69; CYP2C70 = cytochrome P450 2C70; CYP2C71 = cytochrome P450 2C71; CYP2C72 = cytochrome P450 2C72; CYP2C73 = cytochrome P450 2C73; CYP2C74 = cytochrome P450 2C74; CYP2C75 = cytochrome P450 2C75; CYP2C76 = cytochrome P450 2C76; CYP2C77 = cytochrome P450 2C77; CYP2C78 = cytochrome P450 2C78; CYP2C79 = cytochrome P450 2C79; CYP2C80 = cytochrome P450 2C80; CYP2C81 = cytochrome P450 2C81; CYP2C82 = cytochrome P450 2C82; CYP2C83 = cytochrome P450 2C83; CYP2C84 = cytochrome P450 2C84; CYP2C85 = cytochrome P450 2C85; CYP2C86 = cytochrome P450 2C86; CYP2C87 = cytochrome P450 2C87; CYP2C88 = cytochrome P450 2C88; CYP2C89 = cytochrome P450 2C89; CYP2C90 = cytochrome P450 2C90; CYP2C91 = cytochrome P450 2C91; CYP2C92 = cytochrome P450 2C92; CYP2C93 = cytochrome P450 2C93; CYP2C94 = cytochrome P450 2C94; CYP2C95 = cytochrome P450 2C95; CYP2C96 = cytochrome P450 2C96; CYP2C97 = cytochrome P450 2C97; CYP2C98 = cytochrome P450 2C98; CYP2C99 = cytochrome P450 2C99; CYP2C100 = cytochrome P450 2C100; CYP2C101 = cytochrome P450 2C101; CYP2C102 = cytochrome P450 2C102; CYP2C103 = cytochrome P450 2C103; CYP2C104 = cytochrome P450 2C104; CYP2C105 = cytochrome P450 2C105; CYP2C106 = cytochrome P450 2C106; CYP2C107 = cytochrome P450 2C107; CYP2C108 = cytochrome P450 2C108; CYP2C109 = cytochrome P450 2C109; CYP2C110 = cytochrome P450 2C110; CYP2C111 = cytochrome P450 2C111; CYP2C112 = cytochrome P450 2C112; CYP2C113 = cytochrome P450 2C113; CYP2C114 = cytochrome P450 2C114; CYP2C115 = cytochrome P450 2C115; CYP2C116 = cytochrome P450 2C116; CYP2C117 = cytochrome P450 2C117; CYP2C118 = cytochrome P450 2C118; CYP2C119 = cytochrome P450 2C119; CYP2C120 = cytochrome P450 2C120; CYP2C121 = cytochrome P450 2C121; CYP2C122 = cytochrome P450 2C122; CYP2C123 = cytochrome P450 2C123; CYP2C124 = cytochrome P450 2C124; CYP2C125 = cytochrome P450 2C125; CYP2C126 = cytochrome P450 2C126; CYP2C127 = cytochrome P450 2C127; CYP2C128 = cytochrome P450 2C128; CYP2C129 = cytochrome P450 2C129; CYP2C130 = cytochrome P450 2C130; CYP2C131 = cytochrome P450 2C131; CYP2C132 = cytochrome P450 2C132; CYP2C133 = cytochrome P450 2C133; CYP2C134 = cytochrome P450 2C134; CYP2C135 = cytochrome P450 2C135; CYP2C136 = cytochrome P450 2C136; CYP2C137 = cytochrome P450 2C137; CYP2C138 = cytochrome P450 2C138; CYP2C139 = cytochrome P450 2C139; CYP2C140 = cytochrome P450 2C140; CYP2C141 = cytochrome P450 2C141; CYP2C142 = cytochrome P450 2C142; CYP2C143 = cytochrome P450 2C143; CYP2C144 = cytochrome P450 2C144; CYP2C145 = cytochrome P450 2C145; CYP2C146 = cytochrome P450 2C146; CYP2C147 = cytochrome P450 2C147; CYP2C148 = cytochrome P450 2C148; CYP2C149 = cytochrome P450 2C149; CYP2C150 = cytochrome P450 2C150; CYP2C151 = cytochrome P450 2C151; CYP2C152 = cytochrome P450 2C152; CYP2C153 = cytochrome P450 2C153; CYP2C154 = cytochrome P450 2C154; CYP2C155 = cytochrome P450 2C155; CYP2C156 = cytochrome P450 2C156; CYP2C157 = cytochrome P450 2C157; CYP2C158 = cytochrome P450 2C158; CYP2C159 = cytochrome P450 2C159; CYP2C160 = cytochrome P450 2C160; CYP2C161 = cytochrome P450 2C161; CYP2C162 = cytochrome P450 2C162; CYP2C163 = cytochrome P450 2C163; CYP2C164 = cytochrome P450 2C164; CYP2C165 = cytochrome P450 2C165; CYP2C166 = cytochrome P450 2C166; CYP2C167 = cytochrome P450 2C167; CYP2C168 = cytochrome P450 2C168; CYP2C169 = cytochrome P450 2C169; CYP2C170 = cytochrome P450 2C170; CYP2C171 = cytochrome P450 2C171; CYP2C172 = cytochrome P450 2C172; CYP2C173 = cytochrome P450 2C173; CYP2C174 = cytochrome P450 2C174; CYP2C175 = cytochrome P450 2C175; CYP2C176 = cytochrome P450 2C176; CYP2C177 = cytochrome P450 2C177; CYP2C178 = cytochrome P450 2C178; CYP2C179 = cytochrome P450 2C179; CYP2C180 = cytochrome P450 2C180; CYP2C181 = cytochrome P450 2C181; CYP2C182 = cytochrome P450 2C182; CYP2C183 = cytochrome P450 2C183; CYP2C184 = cytochrome P450 2C184; CYP2C185 = cytochrome P450 2C185; CYP2C186 = cytochrome P450 2C186; CYP2C187 = cytochrome P450 2C187; CYP2C188 = cytochrome P450 2C188; CYP2C189 = cytochrome P450 2C189; CYP2C190 = cytochrome P450 2C190; CYP2C191 = cytochrome P450 2C191; CYP2C192 = cytochrome P450 2C192; CYP2C193 = cytochrome P450 2C193; CYP2C194 = cytochrome P450 2C194; CYP2C195 = cytochrome P450 2C195; CYP2C196 = cytochrome P450 2C196; CYP2C197 = cytochrome P450 2C197; CYP2C198 = cytochrome P450 2C198; CYP2C199 = cytochrome P450 2C199; CYP2C200 = cytochrome P450 2C200; CYP2C201 = cytochrome P450 2C201; CYP2C202 = cytochrome P450 2C202; CYP2C203 = cytochrome P450 2C203; CYP2C204 = cytochrome P450 2C204; CYP2C205 = cytochrome P450 2C205; CYP2C206 = cytochrome P450 2C206; CYP2C207 = cytochrome P450 2C207; CYP2C208 = cytochrome P450 2C208; CYP2C209 = cytochrome P450 2C209; CYP2C210 = cytochrome P450 2C210; CYP2C211 = cytochrome P450 2C211; CYP2C212 = cytochrome P450 2C212; CYP2C213 = cytochrome P450 2C213; CYP2C214 = cytochrome P450 2C214; CYP2C215 = cytochrome P450 2C215; CYP2C216 = cytochrome P450 2C216; CYP2C217 = cytochrome P450 2C217; CYP2C218 = cytochrome P450 2C218; CYP2C219 = cytochrome P450 2C219; CYP2C220 = cytochrome P450 2C220; CYP2C221 = cytochrome P450 2C221; CYP2C222 = cytochrome P450 2C222; CYP2C223 = cytochrome P450 2C223; CYP2C224 = cytochrome P450 2C224; CYP2C225 = cytochrome P450 2C225; CYP2C226 = cytochrome P450 2C226; CYP2C227 = cytochrome P450 2C227; CYP2C228 = cytochrome P450 2C228; CYP2C229 = cytochrome P450 2C229; CYP2C230 = cytochrome P450 2C230; CYP2C231 = cytochrome P450 2C231; CYP2C232 = cytochrome P450 2C232; CYP2C233 = cytochrome P450 2C233; CYP2C234 = cytochrome P450 2C234; CYP2C235 = cytochrome P450 2C235; CYP2C236 = cytochrome P450 2C236; CYP2C237 = cytochrome P450 2C237; CYP2C238 = cytochrome P450 2C238; CYP2C239 = cytochrome P450 2C239; CYP2C240 = cytochrome P450 2C240; CYP2C241 = cytochrome P450 2C241; CYP2C242 = cytochrome P450 2C242; CYP2C243 = cytochrome P450 2C243; CYP2C244 = cytochrome P450 2C244; CYP2C245 = cytochrome P450 2C245; CYP2C246 = cytochrome P450 2C246; CYP2C247 = cytochrome P450 2C247; CYP2C248 = cytochrome P450 2C248; CYP2C249 = cytochrome P450 2C249; CYP2C250 = cytochrome P450 2C250; CYP2C251 = cytochrome P450 2C251; CYP2C252 = cytochrome P450 2C252; CYP2C253 = cytochrome P450 2C253; CYP2C254 = cytochrome P450 2C254; CYP2C255 = cytochrome P450 2C255; CYP2C256 = cytochrome P450 2C256; CYP2C257 = cytochrome P450 2C257; CYP2C258 = cytochrome P450 2C258; CYP2C259 = cytochrome P450 2C259; CYP2C260 = cytochrome P450 2C260; CYP2C261 = cytochrome P450 2C261; CYP2C262 = cytochrome P450 2C262; CYP2C263 = cytochrome P450 2C263; CYP2C264 = cytochrome P450 2C264; CYP2C265 = cytochrome P450 2C265; CYP2C266 = cytochrome P450 2C266; CYP2C267 = cytochrome P450 2C267; CYP2C268 = cytochrome P450 2C268; CYP2C269 = cytochrome P450 2C269; CYP2C270 = cytochrome P450 2C270; CYP2C271 = cytochrome P450 2C271; CYP2C272 = cytochrome P450 2C272; CYP2C273 = cytochrome P450 2C273; CYP2C274 = cytochrome P450 2C274; CYP2C275 = cytochrome P450 2C275; CYP2C276 = cytochrome P450 2C276; CYP2C277 = cytochrome P450 2C277; CYP2C278 = cytochrome P450 2C278; CYP2C279 = cytochrome P450 2C279; CYP2C280 = cytochrome P450 2C280; CYP2C281 = cytochrome P450 2C281; CYP2C282 = cytochrome P450 2C282; CYP2C283 = cytochrome P450 2C283; CYP2C284 = cytochrome P450 2C284; CYP2C285 = cytochrome P450 2C285; CYP2C286 = cytochrome P450 2C286; CYP2C287 = cytochrome P450 2C287; CYP2C288 = cytochrome P450 2C288; CYP2C289 = cytochrome P450 2C289; CYP2C290 = cytochrome P450 2C290; CYP2C291 = cytochrome P450 2C291; CYP2C292 = cytochrome P450 2C292; CYP2C293 = cytochrome P450 2C293; CYP2C294 = cytochrome P450 2C294; CYP2C295 = cytochrome P450 2C295; CYP2C296 = cytochrome P450 2C296; CYP2C297 = cytochrome P450 2C297; CYP2C298 = cytochrome P450 2C298; CYP2C299 = cytochrome P450 2C299; CYP2C300 = cytochrome P450 2C300; CYP2C301 = cytochrome P450 2C301; CYP2C302 = cytochrome P450 2C302; CYP2C303 = cytochrome P450 2C303; CYP2C304 = cytochrome P450 2C304; CYP2C305 = cytochrome P450 2C305; CYP2C306 = cytochrome P450 2C306; CYP2C307 = cytochrome P450 2C307; CYP2C308 = cytochrome P450 2C308; CYP2C309 = cytochrome P450 2C309; CYP2C310 = cytochrome P450 2C310; CYP2C311 = cytochrome P450 2C311; CYP2C312 = cytochrome P450 2C312; CYP2C313 = cytochrome P450 2C313; CYP2C314 = cytochrome P450 2C314; CYP2C315 = cytochrome P450 2C315; CYP2C316 = cytochrome P450 2C316; CYP2C317 = cytochrome P450 2C317; CYP2C318 = cytochrome P450 2C318; CYP2C319 = cytochrome P450 2C319; CYP2C320 = cytochrome P450 2C320; CYP2C321 = cytochrome P450 2C321; CYP2C322 = cytochrome P450 2C322; CYP2C323 = cytochrome P450 2C323; CYP2C324 = cytochrome P450 2C324; CYP2C325 = cytochrome P450 2C325; CYP2C326 = cytochrome P450 2C326; CYP2C327 = cytochrome P450 2C327; CYP2C328 = cytochrome P450 2C328; CYP2C329 = cytochrome P450 2C329; CYP2C330 = cytochrome P450 2C330; CYP2C331 = cytochrome P450 2C331; CYP2C332 = cytochrome P450 2C332; CYP2C333 = cytochrome P450 2C333; CYP2C334 = cytochrome P450 2C334; CYP2C335 = cytochrome P450 2C335; CYP2C336 = cytochrome P450 2C336; CYP2C337 = cytochrome P450 2C337; CYP2C338 = cytochrome P450 2C338; CYP2C339 = cytochrome P450 2C339; CYP2C340 = cytochrome P450 2C340; CYP2C341 = cytochrome P450 2C341; CYP2C342 = cytochrome P450 2C342; CYP2C343 = cytochrome P450 2C343; CYP2C344 = cytochrome P450 2C344; CYP2C345 = cytochrome P450 2C345; CYP2C346 = cytochrome P450 2C346; CYP2C347 = cytochrome P450 2C347; CYP2C348 = cytochrome P450 2C348; CYP2C349 = cytochrome P450 2C349; CYP2C350 = cytochrome P450 2C350; CYP2C351 = cytochrome P450 2C351; CYP2C352 = cytochrome P450 2C352; CYP2C353 = cytochrome P450 2C353; CYP2C354 = cytochrome P450 2C354; CYP2C355 = cytochrome P450 2C355; CYP2C356 = cytochrome P450 2C356; CYP2C357 = cytochrome P450 2C357; CYP2C358 = cytochrome P450 2C358; CYP2C359 = cytochrome P450 2C359; CYP2C360 = cytochrome P450 2C360; CYP2C361 = cytochrome P450 2C361; CYP2C362 = cytochrome P450 2C362; CYP2C363 = cytochrome P450 2C363; CYP2C364 = cytochrome P450 2C364; CYP2C365 = cytochrome P450 2C365; CYP2C366 = cytochrome P450 2C366; CYP2C367 = cytochrome P450 2C367; CYP2C368 = cytochrome P450 2C368; CYP2C369 = cytochrome P450 2C369; CYP2C370 = cytochrome P450 2C370; CYP2C371 = cytochrome P450 2C371; CYP2C372 = cytochrome P450 2C372; CYP2C373 = cytochrome P450 2C373; CYP2C374 = cytochrome P450 2C374; CYP2C375 = cytochrome P450 2C375; CYP2C376 = cytochrome P450 2C376; CYP2C377 = cytochrome P450 2C377; CYP2C378 = cytochrome P450 2C378; CYP2C379 = cytochrome P450 2C379; CYP2C380 = cytochrome P450 2C380; CYP2C381 = cytochrome P450 2C381; CYP2C382 = cytochrome P450 2C382; CYP2C383 = cytochrome P450 2C383; CYP2C384 = cytochrome P450 2C384; CYP2C385 = cytochrome P450 2C385; CYP2C386 = cytochrome P450 2C386; CYP2C387 = cytochrome P450 2C387; CYP2C388 = cytochrome P450 2C388; CYP2C389 = cytochrome P450 2C389; CYP2C390 = cytochrome P450 2C390; CYP2C391 = cytochrome P450 2C391; CYP2C392 = cytochrome P450 2C392; CYP2C393 = cytochrome P450 2C393; CYP2C394 = cytochrome P450 2C394; CYP2C395 = cytochrome P450 2C395; CYP2C396 = cytochrome P450 2C396; CYP2C397 = cytochrome P450 2C397; CYP2C398 = cytochrome P450 2C398; CYP2C399 = cytochrome P450 2C399; CYP2C400 = cytochrome P450 2C400; CYP2C401 = cytochrome P450 2C401; CYP2C402 = cytochrome P450 2C402; CYP2C403 = cytochrome P450 2C403; CYP2C404 = cytochrome P450 2C404; CYP2C405 = cytochrome P450 2C405; CYP2C406 = cytochrome P450 2C406; CYP2C407 = cytochrome P450 2C407; CYP2C408 = cytochrome P450 2C408; CYP2C409 = cytochrome P450 2C409; CYP2C410 = cytochrome P450 2C410; CYP2C411 = cytochrome P450 2C411; CYP2C412 = cytochrome P450 2C412; CYP2C413 = cytochrome P450 2C413; CYP2C414 = cytochrome P450 2C414; CYP2C415 = cytochrome P450 2C415; CYP2C416 = cytochrome P450 2C416; CYP2C417 = cytochrome P450 2C417; CYP2C418 = cytochrome P450 2C418; CYP2C419 = cytochrome P450 2C419; CYP2C420 = cytochrome P450 2C420; CYP2C421 = cytochrome P450 2C421; CYP2C422 = cytochrome P450 2C422; CYP2C423 = cytochrome P450 2C423; CYP2C424 = cytochrome P450 2C424; CYP2C425 = cytochrome P450 2C425; CYP2C426 = cytochrome P450 2C426; CYP2C427 = cytochrome P450 2C427; CYP2C428 = cytochrome P450 2C428; CYP2C429 = cytochrome P450 2C429; CYP2C430 = cytochrome P450 2C430; CYP2C431 = cytochrome P450 2C431; CYP2C432 = cytochrome P450 2C432; CYP2C433 = cytochrome P450 2C433; CYP2C434 = cytochrome P450 2C434; CYP2C435 = cytochrome P450 2C435; CYP2C436 = cytochrome P450 2C436; CYP2C437 = cytochrome P450 2C437; CYP2C438 = cytochrome P450 2C438; CYP2C439 = cytochrome P450 2C439; CYP2C440 = cytochrome P450 2C440; CYP2C441 = cytochrome P450 2C441; CYP2C442 = cytochrome P450 2C442; CYP2C443 = cytochrome P450 2C443; CYP2C444 = cytochrome P450 2C444; CYP2C445 = cytochrome P450 2C445; CYP2C446 = cytochrome P450 2C446; CYP2C447 = cytochrome P450 2C447; CYP2C448 = cytochrome P450 2C448; CYP2C449 = cytochrome P450 2C449; CYP2C450 = cytochrome P450 2C450; CYP2C451 = cytochrome P450 2C451; CYP2C452 = cytochrome P450 2C452; CYP2C453 = cytochrome P450 2C453; CYP2C454 = cytochrome P450 2C454; CYP2C455 = cytochrome P450 2C455; CYP2C456 = cytochrome P450 2C456; CYP2C457 = cytochrome P450 2C457; CYP2C458 = cytochrome P450 2C458; CYP2C459 = cytochrome P450 2C459; CYP2C460 = cytochrome P450 2C460; CYP2C461 = cytochrome P450 2C461; CYP2C462 = cytochrome P450 2C462; CYP2C463 = cytochrome P450 2C463; CYP2C464 = cytochrome P450 2C464; CYP2C465 = cytochrome P450 2C465; CYP2C466 = cytochrome P450 2C466; CYP2C467 = cytochrome P450 2C467; CYP2C468 = cytochrome P450 2C468; CYP2C469 = cytochrome P450 2C469; CYP2C470 = cytochrome P450 2C470; CYP2C471 = cytochrome P450 2C471; CYP2C472 = cytochrome P450 2C472; CYP2C473 = cytochrome P450 2C473; CYP2C474 = cytochrome P450 2C474; CYP2C475 = cytochrome P450 2C475; CYP2C476 = cytochrome P450 2C476; CYP2C477 = cytochrome P450 2C477; CYP2C478 = cytochrome P450 2C478; CYP2C479 = cytochrome P450 2C479; CYP2C480 = cytochrome P450 2C480; CYP2C481 = cytochrome P450 2C481; CYP2C482 = cytochrome P450 2C482; CYP2C483 = cytochrome P450 2C483; CYP2C484 = cytochrome P450 2C484; CYP2C485 = cytochrome P450 2C485; CYP2C486 = cytochrome P450 2C486; CYP2C487 = cytochrome P450 2C487; CYP2C488 = cytochrome P450 2C488; CYP2C489 = cytochrome P450 2C489; CYP2C490 = cytochrome P450 2C490; CYP2C491 = cytochrome P450 2C491; CYP2C492 = cytochrome P450 2C492; CYP2C493 = cytochrome P450 2C493; CYP2C494 =

nomas of the breast, the bladder, and the male and female reproductive systems.

**Clinical Toxicities.** The clinical toxicity of vincristine is mostly neurological, as described above. The more severe neurological manifestations may be avoided or reversed by either suspending therapy or reducing the dosage upon occurrence of motor dysfunction. Severe constipation, sometimes resulting in colicky abdominal pain and obstruction, may be prevented by a prophylactic program of laxatives and hydrophilic agents and is usually a problem only with doses above 2 mg/m<sup>2</sup>.

Alopecia occurs in about 20% of patients given vincristine; however, it is always reversible, frequently without cessation of therapy. Although less common than with vinblastine, leukopenia may occur with vincristine, and thrombocytopenia, anemia, polyuria, dysuria, fever, and gastrointestinal symptoms have been reported occasionally. Ischemic cardiac toxicity has been reported. The syndrome of hyponatremia associated with high urinary concentration of Na<sup>+</sup> and inappropriate secretion of antidiuretic hormone occasionally has been observed during vincristine therapy. In view of the rapid action of the vinca alkaloids, it is advisable to take appropriate precautions to prevent the complication of hyperuricemia. This can be accomplished by the administration of allopurinol (see above).

### Vinorelbine

**Vinorelbine (NAVELBINE)** is administered in normal saline as an intravenous infusion of 30 mg/m<sup>2</sup> given over 6 to 10 minutes. It is initially given every week until progression of disease or dose-limiting toxicity when used alone. When used with cisplatin for the treatment of non-small cell lung carcinoma, it is given less frequently (every 4 to 6 weeks). Its primary toxicity is granulocytopenia, with only modest thrombocytopenia and less neurotoxicity than other vinca alkaloids. In experimental studies, it has been given in an oral capsule, but bioavailability is only 30% to 40% (Fumoleau *et al.*, 1993).

### Paclitaxel

This compound, first isolated from the bark of the Western yew tree in 1971 (Wani *et al.*, 1971), exhibits unique pharmacological actions as an inhibitor of mitosis, differing from the vinca alkaloids and colchicine derivatives in that it promotes rather than inhibits microtubule formation. Following its introduction into clinical trial, the drug was approved for treatment of cisplatin-refractory ovarian cancer in 1992 (Rowinsky *et al.*, 1993; Rowinsky and Donehower, 1995) and has promising activity against cancers of the breast, lung, esophagus, and head and neck. The optimal dose, schedule, and use in drug combinations are incompletely understood.

**Chemistry.** Paclitaxel (TAXOL) is a diterpenoid compound that contains a complex taxane ring as its nucleus (Figure 51-13). The side chain linked to the taxane ring at carbon 13 is essential for its





Figure 51-13. Chemical structures of paclitaxel (TAXOL) and its more potent analog, docetaxel (TAXOTERE).

antitumor activity. Modification of the side chain has led to identification of a more potent analog, docetaxel (TAXOTERE) (Figure 51-13), which has clinical activity against breast and ovarian cancers. Originally purified as the parent molecule from yew bark, paclitaxel can now be obtained for commercial purposes by semisynthesis from 10-desacetylbaccatin, a precursor found in yew leaves. It also has been successfully synthesized (Nicolau *et al.*, 1994) from simple off-the-shelf reagents in a complex series of reactions. The molecule has very limited solubility and must be administered in a vehicle of 50% ethanol and 50% polyethoxylated castor oil (Cremophor EL), a formation likely responsible for a high rate of hypersensitivity reactions in patients not protected with both an H<sub>1</sub> antihistamine agent such as diphenhydramine, an H<sub>2</sub> antihistamine agent such as cimetidine (see Chapter 25), and a corticosteroid such as dexamethasone (see Chapter 59).

**Mechanism of Action.** Interest in paclitaxel was stimulated by the finding that the drug possessed the unique ability to promote microtubule formation at cold temperatures and in the absence of GTP. It binds specifically to the  $\beta$ -tubulin subunit of microtubules and appears to antagonize the disassembly of this key cytoskeletal protein, with the result that bundles of microtubules and aberrant structures derived from microtubules appear in paclitaxel-treated cells. Arrest in mitosis follows. Cell killing is dependent on both drug concentrations and duration of cell exposure. Drugs that block the progression of cells through DNA synthesis and into mitosis antagonize the toxic effects of paclitaxel. Schedules for its optimal use in combination

with other drugs, including doxorubicin and cisplatin, have not yet been defined, although the sequence of cisplatin preceding paclitaxel produces greater toxicity than the opposite schedule (Rowinsky *et al.*, 1991). Doxorubicin preceding paclitaxel leads to greater toxicity and less *in vitro* therapeutic effect than the opposite sequence.

In cultured tumor cells, resistance to paclitaxel is associated in some lines with increased expression of the *mdr-1* gene and its product, the P-glycoprotein; other resistant cells have tubulin mutations, and these latter cells may display heightened sensitivity to vinca alkaloids (Cabral, 1983). The basis of clinical drug resistance is not known.

**Absorption, Fate, and Excretion.** Paclitaxel is administered as a 3-hour or 24-hour infusion. Longer infusions (96 hours) have yielded high response rates in breast cancer patients in preliminary trials (Wilson *et al.*, 1994). The drug undergoes intensive P450-mediated hepatic metabolism (isoenzymes CYP3A and CYP2C), and less than 10% of a dose is excreted in the urine intact. The primary metabolite identified thus far is 6-OH paclitaxel, but multiple additional products are found in urine and plasma (Crestell *et al.*, 1994).

Paclitaxel clearance is saturable and decreases with increasing dose or dose rate (Table 51-3). In studies of 96-hour infusion of 35 mg/m<sup>2</sup> per day, the presence of hepatic metastases greater than 2 cm in diameter decreased clearance and led to high drug levels in plasma and greater myelosuppression. Paclitaxel disappears from the plasma compartment with half-lives of approximately 0.2, 2, and 20 hours. The critical plasma concentration for inhibiting bone marrow elements depends on duration of exposure but likely lies in the range of 0.01 to 0.1  $\mu$ M (Huizing *et al.*, 1993).

While precise guidelines for dose reduction in patients with abnormal hepatic function have not been established, 50% to 75% doses should be used in the presence of hepatic metastases greater than 2 cm in size or in patients with abnormal serum bilirubin.

**Therapeutic Uses.** Paclitaxel has undergone initial phases of testing in patients with metastatic ovarian and breast cancer; it has significant activity in both diseases, including diseases in patients that have progressed on standard primary combination regimens. Response rates in relapsed patients range from 20% to 50%, depending on the treatment history and the regimen employed. Early trials indicate significant response rates in lung, head and

neck, esophageal, and bladder carcinomas as well (Arbuck *et al.*, 1993). The optimal schedule of paclitaxel administration, alone or in combination with other drugs, has not been defined.

**Clinical Toxicities.** Paclitaxel exerts its primary toxic effects on the bone marrow. Neutropenia usually occurs 8 to 11 days after a dose and reverses rapidly by days 15 to 21. Used with G-CSF, doses as high as 250 mg/m<sup>2</sup> over 24 hours are well tolerated, and peripheral neuropathy becomes dose-limiting (Kohn *et al.*, 1994). Many patients experience myalgias for several days after receiving paclitaxel. In high-dose schedules, a stocking-glove sensory neuropathy can be disabling, particularly in patients with underlying diabetic or alcoholic neuropathy. Mucositis is prominent in 72- or 96-hour infusions.

Hypersensitivity reactions occurred in patients receiving paclitaxel infusions of short duration (1 to 6 hours) but have largely been averted by pretreatment with dexamethasone, diphenhydramine, and cimetidine, as noted above. Premedication is not necessary with 96-hour infusion. Many patients experience asymptomatic bradycardia, and occasional episodes of silent ventricular tachycardia also occur and resolve spontaneously during 3- or 24-hour infusions.

## EPIPODOPHYLLOTOXINS

Podophyllotoxin, extracted from the mandrake plant (mayapple; *Podophyllum peltatum*), was used as a folk remedy by the American Indians and early colonists for its emetic, cathartic, and anthelmintic effects. Two semisynthetic glycosides of the active principle, podophyllotoxin, have been developed that show significant therapeutic activity in several human neoplasms, including pediatric leukemia, small cell carcinomas of the lung, testicular tumors, Hodgkin's disease, and large cell lymphomas. These derivatives are referred to as *etoposide* (VP-16-213) and *teniposide* (VM-26). Although podophyllotoxin binds to tubulin at a site distinct from that for interaction with the vinca alkaloids, etoposide and teniposide have no effect on microtubular structure or function at usual concentrations. (For review of the epipodophyllotoxins, see Pommier *et al.*, 1995).

Table 51-3  
Paclitaxel Clearance as a Function of Drug Infusion Rate

SCHEDULE	INFUSION RATE, mg/m <sup>2</sup> PER HOUR	PLASMA CLEARANCE, ml/min per m <sup>2</sup>
1. 175 mg/m <sup>2</sup> over 3 hours	58	212
2. 175 mg/m <sup>2</sup> over 24 hours	7	393
3. 140 mg/m <sup>2</sup> over 96 hours	1.5	471